TechDogs-"DIA To Address AI, Supply Chain, Equitable Drug Development At Canada Annual Meeting"

Pharmaceutical Technology

DIA To Address AI, Supply Chain, Equitable Drug Development At Canada Annual Meeting

By Business Wire

Business Wire
Overall Rating

Health Canada, FDA regulators will provide clarity into recent policy updates during interactive panel sessions

WASHINGTON--(BUSINESS WIRE)--DIA will deliver a comprehensive overview of the most pressing regulatory, clinical, and pharmacovigilance challenges facing the healthcare industry, including artificial intelligence (AI) and the global supply chain, during its 21st Canada Annual Meeting on Nov. 7-8 at the Ottawa Conference and Event Centre in Ottawa, Ontario.

This signature event will bring life sciences professionals together to discuss several imperative topics, such as how to implement AI into their processes and procedures, recent progress in equitable drug development and regulatory systems, improving diversity and access in clinical trials, and the presence of nitrosamine impurities in certain drug products.

As in previous years, attendees will be able to discuss policy updates and priorities directly with Health Canada regulators. They will also be able to build and foster relationships with life sciences professionals while gaining additional insights, education, and knowledge to navigate relevant challenges and opportunities in their occupations.

"The rapid pace of technological advancement in healthcare, pharmaceuticals, and biotechnology has led to a near-constant evolution in the regulations that guide each ecosystem," said Tamei Elliott, Associate Director, Scientific Programs of DIA Americas. "The Canada Annual Meeting will again bring hundreds of stakeholders together so they can continue to innovate, affect change, and formulate solutions that elevate care for those who are at the center of what we do every day — the patients."

One of the meeting's many highlights will be a panel discussion featuring Joseph Kim, the Chief Strategy Officer at ProofPilot, titled "Clinical Trials: Focus on Patients, Innovation and Automation." That discussion, which will take place during Session 7, will demonstrate the impact digital protocol automation has on the site and patient experience.

Kim has extensive pharmaceutical research industry knowledge, familiarity with all phases of clinical research, and a well-known history of innovation. His panel was arranged by Vatche Bartekian, the President of Vantage BioTrials and a member of the Canada Annual Meeting program committee who has contributed his insights into drug development to the pharmaceutical and medical device industry for more than 24 years.

The annual meeting will begin with three can't-miss conversations:

"The Future of Therapeutic Products Development: Current Emerging Trends and Technologies" (Session 1): A plenary session featuring representatives from Health Canada and the United States Food and Drug Administration (FDA) that will allow participants to ask questions about the latest regulatory requirements in this area.
"Advancing Agile Regulations for Drugs: Updates from Health Canada" (Session 2): A conversation that will include insight from regulators on the nation's agile licensing for drugs initiative.
"Integrating Equity, Diversity and Inclusion Across the Drug Product Lifecycle" (Session 3): A panel discussion that will spotlight viewpoints from Canada, the United States, and the United Kingdom on how government, industry, and patients are supporting the creation of more equitable drug development and regulatory systems.

To register for DIA's Canada Annual Meeting, visit https://www.diaglobal.org/conference-listing/meetings/2023/11/canada-annual-meeting.

About DIA

DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.

DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan).

Learn more at DIAglobal.org and connect with DIA on X, LinkedIn, Facebook, and Instagram.

Contacts

Denise DiMeglio
610-228-2102
denise@gregoryfca.com

First published on Mon, Oct 30, 2023

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs’ members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs’ Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs’ site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.

Tags:

DIA Pharmaceutical Manufacturing Pharmacovigilance Healthcare Biotechnology

References:

Join The Discussion

  • Dark
  • Light